Abdullah S Madhun

Summary

Affiliation: Institute of Marine Research
Country: Norway

Publications

  1. ncbi Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice
    Abdullah S Madhun
    Influenza Centre, The Gade Institute, University of Bergen, N 5021 Bergen, Norway
    Vaccine 29:4973-82. 2011
  2. ncbi A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine
    Rebecca J Cox
    Influenza Centre, The Gade Institute, University of Bergen, N 5021 Bergen, Norway
    Vaccine 27:1889-97. 2009
  3. ncbi Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice
    Abdullah S Madhun
    Influenza Centre, The Gade Institute, University of Bergen, N 5021 Bergen, Norway
    Vaccine 27:7367-76. 2009
  4. ncbi Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial
    Rebecca J Cox
    Influenza Centre, The Gade Institute, University of Bergen, N 5021 Bergen, Norway
    Vaccine 29:8049-59. 2011
  5. ncbi The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants
    Asne Jul-Larsen
    Influenza Centre, The Gade Institute, University of Bergen, Bergen, Norway
    Hum Vaccin Immunother 8:653-61. 2012
  6. ncbi T-helper 1 cells elicited by H5N1 vaccination predict seroprotection
    Gabriel K Pedersen
    The Gade Institute, Haukeland University Hospital, Bergen, Norway
    J Infect Dis 206:158-66. 2012
  7. ncbi Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model
    Gabriel Pedersen
    Influenza Centre, The Gade Institute, University of Bergen, Bergen, Norway
    Influenza Other Respi Viruses 5:426-37. 2011
  8. ncbi An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers
    Abdullah S Madhun
    Influenza Centre, The Gade Institute, University of Bergen, N 5021 Bergen, Norway
    Vaccine 29:266-73. 2010
  9. ncbi A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models
    Rebecca J Cox
    Influenza Centre, The Gade Institute, University of Bergen, Bergen, Norway
    Influenza Other Respi Viruses 3:107-17. 2009

Collaborators

Detail Information

Publications9

  1. ncbi Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice
    Abdullah S Madhun
    Influenza Centre, The Gade Institute, University of Bergen, N 5021 Bergen, Norway
    Vaccine 29:4973-82. 2011
    ..Our results highlight that c-di-GMP is a promising mucosal adjuvant for pandemic influenza vaccine development...
  2. ncbi A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine
    Rebecca J Cox
    Influenza Centre, The Gade Institute, University of Bergen, N 5021 Bergen, Norway
    Vaccine 27:1889-97. 2009
    ..In conclusion, our study shows that producing effective H7 pandemic vaccines is as challenging as has been observed for H5 vaccines...
  3. ncbi Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice
    Abdullah S Madhun
    Influenza Centre, The Gade Institute, University of Bergen, N 5021 Bergen, Norway
    Vaccine 27:7367-76. 2009
    ..Our results highlight that Matrix-M adjuvant is a promising parenteral adjuvant for formulating pandemic candidate vaccines...
  4. ncbi Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial
    Rebecca J Cox
    Influenza Centre, The Gade Institute, University of Bergen, N 5021 Bergen, Norway
    Vaccine 29:8049-59. 2011
    ..In conclusion, Matrix M™ adjuvant was well tolerated and augmented the antibody response allowing considerable dose sparing down to 1.5 μg HA...
  5. ncbi The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants
    Asne Jul-Larsen
    Influenza Centre, The Gade Institute, University of Bergen, Bergen, Norway
    Hum Vaccin Immunother 8:653-61. 2012
    ..We conclude that the tobacco derived recombinant HAC1 antigen is a promising vaccine candidate recognized by both B- and T cells...
  6. ncbi T-helper 1 cells elicited by H5N1 vaccination predict seroprotection
    Gabriel K Pedersen
    The Gade Institute, Haukeland University Hospital, Bergen, Norway
    J Infect Dis 206:158-66. 2012
    ..An immunological marker for H5N1 vaccine effectiveness is needed for early identification of the best vaccine candidate...
  7. ncbi Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model
    Gabriel Pedersen
    Influenza Centre, The Gade Institute, University of Bergen, Bergen, Norway
    Influenza Other Respi Viruses 5:426-37. 2011
    ..As regulatory authorities have not yet approved a surrogate correlate of protection for H5N1 vaccines, it is important to test the protective efficacy of candidate H5N1 vaccines in a viral challenge study...
  8. ncbi An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers
    Abdullah S Madhun
    Influenza Centre, The Gade Institute, University of Bergen, N 5021 Bergen, Norway
    Vaccine 29:266-73. 2010
    ..A rapid induction of protective antibody is important in reducing community spread of pandemic influenza and in helping maintain the integrity of the health care system during the pandemic...
  9. ncbi A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models
    Rebecca J Cox
    Influenza Centre, The Gade Institute, University of Bergen, Bergen, Norway
    Influenza Other Respi Viruses 3:107-17. 2009
    ..In recent years, several avian influenza subtypes (H5, H7 and H9) have transmitted directly from birds to man, posing a pandemic threat...